{
  "epilepsy_guidelines": {
    "ilae_2025_classification": {
      "source": "ILAE 2025 Updated Classification",
      "url": "https://www.ilae.org/files/dmfile/updated-classification-of-epileptic-seizures-2025.pdf",
      "content": {
        "seizure_classes": {
          "focal": "Focal seizures originate within networks limited to one hemisphere. Classify as focal aware (consciousness retained) or focal impaired awareness (consciousness affected). Focal seizures may evolve to bilateral tonic-clonic.",
          "generalized": "Generalized seizures originate within and rapidly engage bilaterally distributed networks. Subtypes: Motor (tonic-clonic, absence, myoclonic, atonic, tonic, clonic, epileptic spasms) and Non-motor (absence typical/atypical).",
          "unknown_onset": "Unknown whether focal or generalized. Use when onset not witnessed or observed. May later be reclassified with additional information.",
          "unclassified": "Unclassified when insufficient information available to place in other categories."
        },
        "key_updates_2025": "Maintains 2017 framework with refinements for clinical practice. Emphasizes flexibility for diverse settings including resource-limited areas.",
        "absence_seizures": {
          "typical": "Brief behavioral arrest with 3-4 Hz generalized spike-wave, duration usually <10 seconds, abrupt onset/offset.",
          "atypical": "More gradual onset/offset, associated with slower spike-wave (1.5-2.5 Hz), often longer duration, more prominent motor components."
        },
        "focal_to_bilateral": "Focal seizure that evolves to involve both hemispheres with bilateral tonic-clonic activity. Important to recognize focal origin for treatment."
      }
    },
    "first_line_medications": {
      "generalized_tonic_clonic": ["Valproate", "Levetiracetam", "Lamotrigine"],
      "absence": ["Ethosuximide", "Valproate"],
      "focal_seizures": ["Levetiracetam", "Lamotrigine", "Carbamazepine", "Oxcarbazepine"],
      "juvenile_myoclonic": ["Valproate", "Levetiracetam", "Topiramate"],
      "avoid_in_absence": ["Carbamazepine", "Oxcarbazepine", "Phenytoin"],
      "note": "Valproate avoided in women of childbearing potential due to teratogenicity"
    },
    "drug_resistant_epilepsy": {
      "definition": "Failure of adequate trials of two appropriately chosen and tolerated anti-seizure medication schedules (whether as monotherapies or in combination) to achieve sustained seizure freedom.",
      "next_steps": [
        "Reassess diagnosis and classification",
        "Consider epilepsy surgery evaluation if focal",
        "Neurostimulation (VNS, RNS, DBS)",
        "Dietary therapies (ketogenic diet)",
        "Clinical trial participation"
      ]
    }
  },
  "parkinsons_guidelines": {
    "motor_symptoms": {
      "cardinal_features": "Rest tremor (4-6 Hz), bradykinesia (required for diagnosis), rigidity, postural instability",
      "hoehn_yahr_staging": {
        "stage_1": "Unilateral involvement only",
        "stage_2": "Bilateral involvement without balance impairment",
        "stage_3": "Mild to moderate disease; some postural instability; physically independent",
        "stage_4": "Severe disability; still able to walk or stand unassisted",
        "stage_5": "Wheelchair bound or bedridden unless aided"
      }
    },
    "medication_management": {
      "initial_therapy": {
        "under_65": "Consider MAO-B inhibitors or dopamine agonists to delay levodopa",
        "over_65": "Levodopa/carbidopa often first-line due to better efficacy and tolerability",
        "consideration": "Quality of life and functional impairment guide timing"
      },
      "levodopa_formulations": {
        "immediate_release": "Duration 3-4 hours, dosed TID-QID, standard initial formulation",
        "extended_release": "Rytary (IPX203): 4-6 hour duration, combines IR and ER beads, useful for wearing-off",
        "other_options": "Inbrija (inhaled), Parcopa (ODT) for rescue therapy"
      },
      "motor_complications": {
        "wearing_off": "End-of-dose return of symptoms. Management: COMT inhibitor, MAO-B inhibitor, increase frequency, ER formulation",
        "dyskinesias": "Peak-dose involuntary movements. Management: Amantadine, lower individual doses, fractionation, consider DBS",
        "on_off_fluctuations": "Unpredictable motor fluctuations. Consider apomorphine rescue, continuous dopaminergic delivery"
      }
    },
    "non_motor_symptoms": {
      "autonomic": "Constipation, urinary dysfunction, orthostatic hypotension, sexual dysfunction",
      "neuropsychiatric": "Depression (30%), anxiety, apathy, psychosis, impulse control disorders",
      "sleep": "REM sleep behavior disorder, insomnia, excessive daytime sleepiness, restless legs",
      "cognitive": "Mild cognitive impairment in 20-30%, dementia develops in 30-80% long-term",
      "treatment_approaches": "Target specific symptoms, avoid medications that worsen parkinsonism"
    }
  },
  "stroke_guidelines": {
    "acute_treatment": {
      "iv_thrombolysis": {
        "indication": "Acute ischemic stroke within 4.5 hours of symptom onset",
        "dose": "Alteplase 0.9 mg/kg (max 90mg), 10% bolus, 90% infusion over 60 minutes",
        "key_exclusions": "ICH, recent surgery, active bleeding, BP >185/110, platelets <100K",
        "extended_window": "Consider 4.5-9 hours in select patients with perfusion imaging mismatch"
      },
      "mechanical_thrombectomy": {
        "indication": "Large vessel occlusion (ICA, M1, M2, basilar) within 24 hours if imaging criteria met",
        "time_windows": "0-6 hours: all eligible LVOs, 6-24 hours: selected patients with favorable imaging",
        "technique": "Stent retriever or aspiration, goal <90 minutes door-to-groin"
      }
    },
    "nihss_interpretation": {
      "mild": "0-4 points: Minor stroke or TIA",
      "moderate": "5-15 points: Moderate stroke",
      "moderate_severe": "16-20 points: Moderate to severe stroke",
      "severe": "21-42 points: Severe stroke",
      "note": "NIHSS may underestimate posterior circulation strokes (ataxia, vertigo not well captured)"
    },
    "secondary_prevention": {
      "antiplatelet": {
        "acute": "Aspirin 325mg within 24-48 hours if not thrombolysed",
        "high_risk_tia": "Aspirin 325mg + clopidogrel 75mg x 21 days, then single agent",
        "long_term": "Aspirin 81mg, clopidogrel 75mg, or aspirin-dipyridamole"
      },
      "anticoagulation": {
        "atrial_fibrillation": "Direct oral anticoagulant (DOAC) preferred over warfarin",
        "timing": "Generally start 4-14 days post-stroke depending on infarct size and hemorrhage risk"
      },
      "statins": "High-intensity statin regardless of cholesterol level for atherosclerotic stroke",
      "blood_pressure": "Target <140/90 for secondary prevention, <130/80 if additional vascular risk"
    },
    "tia_management": {
      "abcd2_score": "Age, BP, Clinical features, Duration, Diabetes - stratifies short-term stroke risk",
      "urgent_evaluation": "All TIA patients require urgent evaluation within 24-48 hours",
      "imaging": "MRI with DWI preferred (30-50% show acute infarct), vascular imaging mandatory",
      "capsular_warning_syndrome": "Recurrent stereotyped TIAs from capsular ischemia, very high stroke risk, urgent antiplatelet therapy"
    }
  },
  "headache_guidelines": {
    "ichd3_migraine": {
      "migraine_without_aura": {
        "criteria": "A: ≥5 attacks, B: Duration 4-72hr, C: ≥2 of (unilateral, pulsating, moderate-severe intensity, aggravated by routine activity), D: ≥1 of (nausea/vomiting, photophobia and phonophobia)",
        "differential": "Must not be better explained by another ICHD-3 diagnosis"
      },
      "migraine_with_aura": {
        "visual_aura": "Most common: zigzag lines (fortification spectra), scotoma, gradual spread over 5-60 min",
        "sensory_aura": "Pins-and-needles, numbness, typically spreading",
        "speech_aura": "Dysphasic speech",
        "timing": "Aura develops gradually over ≥5 min, multiple symptoms spread over ≥5 min each, each symptom lasts 5-60 min"
      }
    },
    "cluster_headache": {
      "diagnostic_criteria": "Severe unilateral orbital/supraorbital/temporal pain lasting 15-180 min untreated, with ≥1 ipsilateral autonomic feature (conjunctival injection, lacrimation, nasal congestion, rhinorrhea, forehead/facial sweating, miosis, ptosis, eyelid edema) and/or restlessness/agitation",
      "patterns": {
        "episodic": "Cluster periods lasting 7 days to 1 year separated by pain-free periods ≥3 months",
        "chronic": "Attacks for >1 year without remission or with remissions <3 months"
      },
      "treatment": {
        "acute": "100% oxygen 12 L/min x 15 min, sumatriptan 6mg SC (most effective)",
        "transitional": "Corticosteroids (prednisone) for rapid control at cluster onset",
        "preventive": "Verapamil (titrate to 240-960mg/day with EKG monitoring), lithium for chronic cluster"
      }
    }
  },
  "metadata": {
    "compiled_date": "2026-02-13",
    "sources": [
      "ILAE 2025 Updated Seizure Classification",
      "American Academy of Neurology (AAN) Guidelines",
      "ICHD-3 (International Classification of Headache Disorders, 3rd edition)",
      "AHA/ASA Stroke Guidelines 2019-2024 updates",
      "Movement Disorder Society Evidence-Based Reviews"
    ],
    "note": "Summaries of key guideline points for prompt engineering context. Refer to original sources for complete clinical decision-making."
  }
}
